Clinical Trial Update: Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) [Phase 2]

View source ↗

Summary

Phase 2 results for a combination of pegylated liposomal doxorubicin, low-frequency dexamethasone, and lenalidomide (Dd-R) in newly diagnosed multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)
• Revlimid (lenalidomide)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2013-12-17